The Future of Genetics and Heart Disease
SEPTEMBER 24, 2020 | 12:00 PM – 1:30 PM ET
The inaugural session of the FH Foundation’s 2020 FH Global Summit will honor Dr. Robert A. Hegele with the 2020 FH Pioneer Award for his achievements in cardiovascular genetics including key discoveries of the genetic basis of several human lipid disorders. Dr. Hegele will give a keynote address on the drivers of inherited heart disease, which will be followed by a conversation with Drs. Daniel Rader and Joshua Knowles and audience Q & A.
Unlocking the Potential of Precision Health for Diverse Populations
OCTOBER 22, 2020 | 12:00 PM – 1:30 PM ET
Precision medicine holds the promise to revolutionize clinical care but only if all populations can share in those benefits. While FH and high lipoprotein(a) impact all races and ethnicities, contemporary studies (including from the FH Foundation’s CASCADE FH longitudinal study) continue to demonstrate unacceptable disparities in care particularly for Black, Asian and Latin populations and for women. Join Dr. Latrice Landry for a provocative discussion about overcoming the challenges of disparities in care.
Can Behavioral Economics Drive Cardiovascular Disease Prevention?
NOVEMBER 19, 2020 | 12:00 PM – 1:30 PM ET
Guidelines and therapies can be effective and still not be implemented if barriers to prescribing are not removed. An individual “patient” spends 5,000 hours without a healthcare provider making their own daily choices to improve their health or take their medication. Is it possible to align these stakeholders? Join us to hear from Dr. Kevin Volpp about how health incentives, behavioral economics, and “nudges” can improve cardiovascular health. This session will include a dynamic discussion with diverse healthcare stakeholders.
Lp(a) and Drivers of Inherited Risk
JANUARY 27, 2021 | 12:00 PM – 1:30 PM ET
Lipoprotein (a), Lp(a), is an important independent risk factor for premature atherosclerotic cardiovascular disease (ASCVD), including heart attacks, stroke and calcific aortic valve stenosis. Guidelines on whom to screen for Lp(a) are evolving and new therapies are emerging.
New Frontiers of FH Care
FEBRUARY 17, 2021 | 12:00 PM – 1:30 PM ET
Can gene editing with CRISPR technology help fight cardiovascular disease? Can looking beyond the known FH genes help personalize risk assessment? Join Dr. Kiran Musunuru, Penn Medicine, and Dr. Amit V. Khera, Broad Institute, as we discuss and debate.
Implementing Innovations in FH Care
MARCH 17, 2021 | 12:00 PM – 1:30 PM ET
Implementation science provides an opportunity to change behaviors of both clinicians and patients. Join Dr. Meghan Lane-Fall, Penn Medicine, Dr. Laney Jones, Geisinger, and Dr. Brian Mittman, Kaiser Permanente, for a dynamic discussion on improving healthcare delivery through implementation science.
APRIL 21, 2021 | 12:00 PM – 1:30 PM ET
According to the FH Foundation national database, over 5 million people with familial hypercholesterolemia and cardiovascular disease do not achieve guideline-recommended LDL-cholesterol levels. Join Dr. John Kastelein, Professor of Medicine at the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam, and our expert roundtable for an overview of new and emerging treatments.
Activating Family Screening
MAY 19, 2021 | 12:00 PM – 1:30 PM ET
More information coming soon!